Research, Charts & Company Announcements
Research Tree provides access to ongoing research coverage, media content and regulatory news on GAZTRANSPORT ET TECHNIGA SA. We currently have 3 research reports from 1 professional analysts.
Frequency of research reports
Research reports on
GAZTRANSPORT ET TECHNIGA SA
GAZTRANSPORT ET TECHNIGA SA
Revenue 2016 guidance cut to c. €240m
22 Jul 16
Q2 revenues were €46m (H1 +11.4% yoy; royalties +15.2% and services -32.2% due to the base effect). GTT received two new orders during the quarter (none in Q1) and the order book now stands at 107 units. The EBIT margin came in at 61.7% and the net margin at 51.8%; both were stable. Guidance has been changed: - Revenue 2016 at c. €240m vs. previous growth of at least 10% (i.e. >€250m); - Net margin 2016 above 50%, confirmed; - Dividend for 2016 and 2017 at least at the level of 2015 (€2.66 per share), confirmed.
Guidance 2016 confirmed, no new orders during Q1 16
13 Apr 16
Q1 revenues were €59m (+7.1% yoy), of which €55m from royalties (+9.4% yoy) and €3m from services (-22% yoy, as the contribution in Q1 15 was particularly high). The company didn’t receive any new orders during the quarter. Guidance is confirmed: - revenue 2016 growth of at least 10% (i.e. >€250m); - net margin above 50%; - dividend for 2016 and 2017 at least at the level proposed for 2015 (€2.66 per share).
Initiating coverage of GTT.
22 Feb 16
GTT (market cap: €951m) is the global leader in the field of LNG containment systems. GTT derives around >90% of its revenues from royalty fees paid by clients using its technology in LNG projects, mainly carriers (LNGC and VLEC), accounting for c. 80% of the company’s revenues. We initiate coverage with an ADD recommendation and 12% upside. GTT’s business model, based on intellectual property, underlies a virtually infinite ROCE and 52% net margin in 2015. While the return and margins are a result of entry barriers and pricing moat, the main concern relates to the LNG fleet investment cycle, as the order book may have peaked. GTT is likely to go through to a down-cycle which would see a contraction in order intake over the next three years. At a low, the company could become an LBO target for a buyer attracted by an option on the LNG capacity cycle, which itself is linked to LNG prices.
The Slide Rule
12 Jan 17
What is The Slide Rule? The Slide Rule has been designed to dramatically simplify the identification of the best companies in the UK small/mid-cap sector by making a quantitative assessment of the relative potential of each company. At its core, The Slide Rule aims to identify those companies that create genuine shareholder value through strong returns on capital and solid growth, but also present a value opportunity with the potential tailwind of earnings momentum. Companies are assessed within a Quality, Value, Growth and Momentum (QVGM) framework.
16 Jan 17
We take a look at the rankings of the various countries in Africa that have a significant exposure to mining. We take the Transparency International corruption rankings as our starting point and modify these for exceptional geology and for current UK government travel warnings. Ghana, Botswana and Namibia come out as our top three, with Eritrea, Kenya and Zimbabwe at the bottom of our rankings.
Small Cap Breakfast
17 Jan 17
Global Energy Development (GED.L) — To be renamed Nautilus Marine Services. Schedule 1 from developer and seller of hydrocarbons and related products. Reverse takeover. Raising $10.5m via a convertible. Expected 9 Feb. Eco (Atlantic) Oil & Gas—TSX-V listed oil and gas exploration has announced its intention to float on AIM. Assets in Guyana and Namibia. Proposed £2m-£3m fundraise. Diversified Gas & Oil—According to LSE website first day of trading on AIM now expected for 30 January.
N+1 Singer - St Ives - Downgrade
19 Jan 17
Marketing activation has been impacted by further decline in grocery retail impacting profit by c£5m. Strategic The Company is also taking this opportunity to revise its guidance for Strategic Marketing as its recovery pace is not running at the planned target rate. PBT falls from N1Se £31.9m to £25m. The Company expects dividend to be held based upon lowered guidance and the implied cash flow performance. There do not appear to be any covenant issues. Forecasts and TP under review and downgrade to Hold. We expect the shares to test the 100p level.
N+1 Singer - Northern lights - Shining prospects for 2017
16 Jan 17
As the birthplace of Stephenson, Armstrong and Swan, the North East of England has a proud history of industrial and technological innovation. Despite local economic challenges, the region’s industrial heritage lives on through continuing success in high end engineering and technology. The recent takeovers of private equity backed SMD (subsea robotics) and Nomad Digital (wi-fi on the railways) are testament to this. The North East has also emerged as a leader in genetics and genomics with an enviable life sciences and healthcare infrastructure. Against this backdrop, we expect the region to continue to throw up attractive IPO candidates to build on the six new listings in the past three years. We expect 2017 to be far kinder to the existing portfolio of North East plcs than 2016 (a year to forget) with recent management changes one important theme for the new year. Our top picks are Hargreaves Services, Quantum Pharma and Zytronic (all N+1 Singer Corporate clients) and we are Buyers of Northgate and Grainger.
N+1 Singer - Morning Song 19-01-2017
19 Jan 17
Actual Experience (ACT LN) 2017 – a milestone year for revenue | Bagir Group (BAGR LN) Independent NED appointment to strengthen Board composition | Bioquell (BQE LN) Reassuring pre-close statement | Carador Income Fund (CIFU LN) Q4 dividend increased to 2.75c, 0.5c higher than forecast | FreeAgent (FREE LN) Contract with Royal Bank of Scotland | Halfords Group (HFD LN) Excellent Q3 update, special divi and confidence in FX mitigations | N Brown Group (BWNG LN) Robust peak trading with reversal of drag from older titles | NCC Group (NCC LN) Interims confirm underlying business sound | St Ives (SIV LN) Downgrade | Summit Therapeutics (SUMM LN) Dr David Roblin appointed Chief Operating Officer and R&D President | Wilmington Group (WIL LN) Acquisition – Further scaling of Healthcare